Borgeson Blake 4
4 · RECURSION PHARMACEUTICALS, INC. · Filed Jul 9, 2026
Research Summary
AI-generated summary of this filing
Recursion Pharmaceuticals (RXRX) Director Blake Borgeson Sells 40,000 Shares
What Happened
- Blake Borgeson, a director of Recursion Pharmaceuticals (RXRX), sold 40,000 shares in an open-market transaction on July 7, 2026. The weighted average sale price was $3.96 per share for total proceeds of approximately $158,500. This was a sale (code S), not a purchase.
Key Details
- Transaction date: July 7, 2026.
- Prices: executed in multiple trades at $3.95–$4.00; reported weighted average price $3.96 (total ≈ $158,500). The filer will provide per-trade breakdown on request (see footnote).
- Shares owned after transaction: not disclosed in the information provided in this summary.
- Footnotes: (F1) Sale was made pursuant to a Rule 10b5-1 trading plan adopted August 31, 2025. (F2) Multiple trades at $3.95–$4.00; weighted-average price reported.
- Timeliness: Form 4 was filed July 9, 2026 (within the typical two-business-day filing window).
Context
- The sale was executed under a pre-established 10b5-1 plan, which often indicates the transactions were prearranged and not necessarily a reflection of current sentiment. Sales are generally less informative than purchases about insider confidence in the company’s prospects.
Insider Transaction Report
Form 4
Borgeson Blake
Director
Transactions
- Sale
Class A Common Stock
[F1][F2]2026-07-07$3.96/sh−40,000$158,500→ 6,218,287 total
Footnotes (2)
- [F1]This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025.
- [F2]This transaction was executed in multiple trades at prices ranging from $3.95 to $4.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Signature
/s/Jonathan Golightly, attorney-in-fact|2026-07-09